Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Laser Vision Centers, Inc. (NASDAQ: LVCI) -- Ignore unavailable to you. Want to Upgrade?

To: James Ratzliff who wrote (135)	4/17/1998 10:23:00 PM
From: Jim Mac	Respond to of 413

Please don't confuse me, Jim Mac, with Mac. I am Jim Mac, I am not Mac. Mac is not me, and I am not Mac. All this Mac yak is making my lips smak for a Big Mac.

To: James Ratzliff who wrote (135)	4/18/1998 7:03:00 PM
From: Jim Mac	Read Replies (2) \| Respond to of 413

LVCI should be trading at more than $15 now, if LZRCF and LCAV are at fair market value. LVCI is doing over 130 procedures per laser per month (1500+ annualized) vs about 50 for LZRCF and LCAV. LVCI is now generating about $1M cash per Q, LZRCF and LCAV just turning EBITDA positive. LVCI doing over 10% U.S. procedures with only 5% lasers, LZRCF 10% with 10% lasers, LCAV 5% with 5% lasers. LVCI can enter and exit new markets without risk, and has broadest geographic coverage. 1999 fully-taxed EPS $1.00, up to $1.50 with hyperopia, and this excludes acquisitions and more contracts. LZRCF is valued at $400M+, LCAV at $125M+, so LVCI should be valued way over its current $124M, because LVCI is the lowest-risk, fastest-growing, and only cash-generating operator now with the strongest growth prospects. LVCI should be trading at a MINIMUM of $15 now, if LZRCF and LCAV are trading at fair market value.